Abstract
In clinical trials, the incidence of epistaxis with intranasal corticosteroid (INS) use is calculated based on 2-6 weeks of usage. Because an INS is typically prescribed for year-round usage, we expected the actual prevalence of epistaxis with INS usage to be significantly higher.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
